Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Background: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic r...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359211072621 |
| _version_ | 1798016053226242048 |
|---|---|
| author | Miguel Burgos Iván Cavero-Redondo Celia Álvarez-Bueno Eva María Galán-Moya Atanasio Pandiella Eitan Amir Alberto Ocaña |
| author_facet | Miguel Burgos Iván Cavero-Redondo Celia Álvarez-Bueno Eva María Galán-Moya Atanasio Pandiella Eitan Amir Alberto Ocaña |
| author_sort | Miguel Burgos |
| collection | DOAJ |
| description | Background: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer. Methods: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction. Results: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51–2.53], and DFS (HR = 2.49, 95% CI = 2.01–3.07) with subgroup analysis showing no significant differences between disease site subgroups. Conclusions: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics. |
| first_indexed | 2024-04-11T15:43:30Z |
| format | Article |
| id | doaj.art-43dce86e5c974886adb6b471146da52d |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-11T15:43:30Z |
| publishDate | 2022-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-43dce86e5c974886adb6b471146da52d2022-12-22T04:15:39ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592022-01-011410.1177/17588359211072621Prognostic value of the immune target CEACAM6 in cancer: a meta-analysisMiguel BurgosIván Cavero-RedondoCelia Álvarez-BuenoEva María Galán-MoyaAtanasio PandiellaEitan AmirAlberto OcañaBackground: Identification of membrane proteins differentially expressed on tumor cells is a key step in drug development. The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein belonging to the immunoglobulin superfamily. Here, we explore the prognostic role CEACAM6 expression on patient outcome in cancer. Methods: A systematic search for studies evaluating the association between tumor expression of CEACAM6 and overall survival (OS) and disease-free survival (DFS) was performed. Hazard ratios (HR) were pooled in a meta-analysis using generic inverse variance and random effect modeling. Subgroup analyses were conducted based on tumor type and method of HR extraction. Results: Sixteen studies met the inclusion criteria. CEACAM6 expression was associated with worse OS [HR = 1.96, 95% confidence interval (CI) = 1.51–2.53], and DFS (HR = 2.49, 95% CI = 2.01–3.07) with subgroup analysis showing no significant differences between disease site subgroups. Conclusions: High expression of CEACAM6 is associated with worse OS and DFS in different malignancies. CEACAM6 is a target for the future development of novel therapeutics.https://doi.org/10.1177/17588359211072621 |
| spellingShingle | Miguel Burgos Iván Cavero-Redondo Celia Álvarez-Bueno Eva María Galán-Moya Atanasio Pandiella Eitan Amir Alberto Ocaña Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis Therapeutic Advances in Medical Oncology |
| title | Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis |
| title_full | Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis |
| title_fullStr | Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis |
| title_full_unstemmed | Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis |
| title_short | Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis |
| title_sort | prognostic value of the immune target ceacam6 in cancer a meta analysis |
| url | https://doi.org/10.1177/17588359211072621 |
| work_keys_str_mv | AT miguelburgos prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT ivancaveroredondo prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT celiaalvarezbueno prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT evamariagalanmoya prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT atanasiopandiella prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT eitanamir prognosticvalueoftheimmunetargetceacam6incancerametaanalysis AT albertoocana prognosticvalueoftheimmunetargetceacam6incancerametaanalysis |